<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(9)</volume><submitter>Medendorp K</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Previously, we identified the mitotic arrest deficient protein MAD2B (MAD2L2) as a bona fide interactor of the renal cell carcinoma (RCC)-associated protein PRCC. In addition, we found that fusion of PRCC with the transcription factor TFE3 in t(X;1)(p11;q21)-positive RCCs results in an impairment of this interaction and, concomitantly, an abrogation of cell cycle progression. Although MAD2B is thought to inhibit the anaphase promoting complex (APC) by binding to CDC20 and/or CDH1(FZR1), its exact role in cell cycle control still remains to be established.&lt;h4>Methodology/principal findings&lt;/h4>Using a yeast two-hybrid interaction trap we identified the small GTPase RAN, a well-known cell cycle regulator, as a novel MAD2B binding protein. Endogenous interaction was establi</pubmed_abstract><journal>PloS one</journal><pagination>e7020</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2737141</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The mitotic arrest deficient protein MAD2B interacts with the small GTPase RAN throughout the cell cycle.</pubmed_title><pmcid>PMC2737141</pmcid><pubmed_authors>Medendorp K</pubmed_authors><pubmed_authors>de Bruijn DR</pubmed_authors><pubmed_authors>van den Hurk WH</pubmed_authors><pubmed_authors>Hetterschijt L</pubmed_authors><pubmed_authors>Brugmans L</pubmed_authors><pubmed_authors>van Groningen JJ</pubmed_authors><pubmed_authors>Vreede L</pubmed_authors><pubmed_authors>van Kessel AG</pubmed_authors></additional><is_claimable>false</is_claimable><name>The mitotic arrest deficient protein MAD2B interacts with the small GTPase RAN throughout the cell cycle.</name><description>&lt;h4>Background&lt;/h4>Previously, we identified the mitotic arrest deficient protein MAD2B (MAD2L2) as a bona fide interactor of the renal cell carcinoma (RCC)-associated protein PRCC. In addition, we found that fusion of PRCC with the transcription factor TFE3 in t(X;1)(p11;q21)-positive RCCs results in an impairment of this interaction and, concomitantly, an abrogation of cell cycle progression. Although MAD2B is thought to inhibit the anaphase promoting complex (APC) by binding to CDC20 and/or CDH1(FZR1), its exact role in cell cycle control still remains to be established.&lt;h4>Methodology/principal findings&lt;/h4>Using a yeast two-hybrid interaction trap we identified the small GTPase RAN, a well-known cell cycle regulator, as a novel MAD2B binding protein. Endogenous interaction was establi</description><dates><release>2009-01-01T00:00:00Z</release><publication>2009 Sep</publication><modification>2026-04-08T03:18:29.281Z</modification><creation>2019-03-26T23:06:20Z</creation></dates><accession>S-EPMC2737141</accession><cross_references><pubmed>19753112</pubmed><doi>10.1371/journal.pone.0007020</doi></cross_references></HashMap>